Iptacopan (Fabhalta) has been shown to slow the decline in kidney function in adult patients with IgA nephropathy. These findings come from final data from a large phase III study called APPLAUSE-IgAN. The study confirmed that the drug met its primary goal of reducing the annual decline in kidney function. Iptacopan is a complement inhibitor that targets the immune system. IgA nephropathy is a disease that affects the kidneys and leads to their failure. The results of the study suggest a potential benefit of iptacopan for patients with this disease.